Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00657033 · ClinicalTrials.gov registry record · Phase 3

Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction

A Phase 3 study of Erectile Dysfunction, sponsored by Bayer.

Completed
Registry status
Phase 3
Development phase
229
Enrollment target
20
Study locations

NCT00657033 is a Phase 3 study of Erectile Dysfunction that has completed, run by Bayer. The registered enrollment target is 229 participants, roughly in line with the 225-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00657033, a Phase 3 study of Erectile Dysfunction, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 3
Development phase
229 participants
Enrollment target
20
Study locations

Study Summary

Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Levitra (Vardenafil, BAY38-9456)

Study Locations (20)

California

  • - Beverly Hills
  • - Irvine
  • - Newport Beach
  • - San Bernardino
  • - San Diego
  • - San Diego

North Carolina

  • - Charlotte
  • - Statesville
  • - Wilmington

Maryland

  • - Greenbelt
  • - Lutherville

New Jersey

  • - Lawrenceville
  • - New Brunswick

Arizona

  • - Phoenix

Connecticut

  • - Trumbull

Florida

  • - Jacksonville

Georgia

  • - Riverdale

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2003-10
Est. Completion 2004-08
Phase Phase 3

Sponsor

Bayer

591 total trials

What the Registry Record Tells You About NCT00657033

The ClinicalTrials.gov registry entry for NCT00657033 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 225-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Erectile Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00657033 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, North Carolina, Maryland.

Frequently Asked Questions

What is clinical trial NCT00657033 about?

NCT00657033 is a clinical study titled "Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction". Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.

What is the current status of trial NCT00657033?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 229 participants. The study started on 2003-10. Estimated completion is 2004-08.

What conditions does trial NCT00657033 study?

This clinical trial studies the following conditions: Erectile Dysfunction.

What interventions are being tested in trial NCT00657033?

The interventions under investigation include: Placebo (DRUG), Levitra (Vardenafil, BAY38-9456) (DRUG).

Who is sponsoring clinical trial NCT00657033?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00657033 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Erectile Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.